Boiron S.A.(0DTF) Stock Analysis

EUR --+0.00%

Reward42Moderate

Risk18Low

75%Data

5.2% dividend yield

Dividend King

Market Cap:426.66M

ⓘ

Reward Rating

Moderate

Reward Assessment

75% data coverage

Bottom 10% of stocksView factors

ⓘ

Risk Rating

Low

Risk Assessment

Risk factors availableUnlock details

Earnings & dividend markersEarnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Boiron S.A.?

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

AI Brief Pro

The brief on Boiron S.A.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Boiron S.A.?

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. The company is listed on the LSE in UK, with a market capitalisation of 426.66M, and a P/E ratio of 0.2x.

Financial Highlights

Investment Breakdown

Growth

Revenue growth is subdued, limiting near-term earnings expansion.

Profitability

Adequate profitability with some margin variability in recent periods.

Risk

Below-average volatility supports a steadier risk profile.

Valuation

Currently trading below intrinsic value estimates, suggesting upside potential.

Analysis

Reward: Moderate (42)